AI-based fluid activity meter drives breakthrough changes in management of neovascular AMD
Click Here to Manage Email Alerts
Regulatory approval of a novel artificial intelligence-based tool that provides precise measurement of retinal fluid may introduce major paradigm changes in the monitoring of patients with neovascular age-related macular degeneration.
“It is a precision management tool, a VEGF meter, which is what Philip Rosenfeld was asking for when anti-VEGF therapies started. More precisely, it is a fluid meter and is now ready for use in clinical practice,” Ursula Schmidt-Erfurth, MD, PhD, told Healio/OSN.
As a tool that every eye specialist can introduce in their daily routine practice, the RetInSight fluid monitor is a milestone in a long-standing research pathway of development and validation of deep learning methods to support the diagnosis and management of retinal disease. Schmidt-Erfurth and her group at the University of Vienna were pioneers in this field and worked on this project for almost a decade.
“Anti-VEGF therapy has been in our hands since 2006. Nevertheless, the real-world outcomes are far below what we expected from the clinical studies, and severe vision loss and blindness have increased by 24% during the last 10 years. This is a learning and a warning,” she said.
In addition, there are no shared evidence-based criteria for re-treatment and injection frequency, and there is no consensus among retina physicians on the best treatment regimen to reduce patient burden, promote compliance and ensure treatment efficacy. The current parameters to determine the treatment interval are not sufficiently objective or reliable, according to Schmidt-Erfurth.
“We have no standard. Everybody is doing their best with a huge variability. There is no real criterion for even highly educated investigators to say whether a patient should be treated or should be put forward to a longer interval. Treatment decisions are based on central retinal thickness, which we know does not correlate with fluid volumes,” Schmidt-Erfurth said.
Fluid activity meter
The RetInSight fluid monitor is a “fluid activity meter,” a detection algorithm that objectively identifies, localizes and quantifies fluid in OCT images on a three-dimensional pixel basis.
“So, we have accurate volumes in nanoliters, we have accurate locations within the central macular area, and each OCT pixel is labeled according to its fluid type as intraretinal fluid (IRF), subretinal fluid (SRF) and/or pigment epithelium detachment when present,” Schmidt-Erfurth said. “It is a personalized, automated, real-time system to identify disease activity and the response to therapy.”
Central retinal thickness is currently used as a surrogate OCT biomarker for disease activity, but particularly in neovascular AMD, what the instrument measures is not the actual 3D fluid pooling. There is no assessment of tridimensionality and no perception of quantity. And yet, accurate, dynamic fluid representation and fluid control are critical in neovascular AMD. A study by Chakravarthy and colleagues showed worsening of visual acuity over 2 years associated with dynamic volume fluctuations in retinal fluid volumes during the maintenance phase.
“It’s the ups and downs that cause the vision loss, and these changes need to be objectively measured. They cannot be assessed by even the best expert,” Schmidt-Erfurth said. “With the fluid monitor, we are introducing a standard, and that means that we have objective criteria that allow us to treat as much as needed but as little as possible and to do that at the right time interval.”
Schmidt-Erfurth does not agree with a large part of the community that has “fled toward treat-and extend,” which means treating a dry retina in many cases. In medicine, giving a drug when it is not needed is never a good idea, she said, and a drug that has to be injected into people’s eyes hundreds of times over a lifetime should preferably be administered when there is active fluid.
“And fluid has to be measured, so that the new standard would be not to treat a dry retina. The other standard would be to learn that fluid comes in different compartments. Even this very basic truth is not respected in the standards we have now. We just treat any fluid, although we are learning that IRF and SRF have distinct functional implications and that IRF is more consistently associated with worse visual outcomes. We may introduce a standard that only treats dynamic fluid and not persistent SRF, which may even be good as long as it remains stable,” Schmidt-Erfurth said.
Tool for clinical practice, clinical trials
The new tool is meant to be a practical support for clinicians in their treatment decision-making process. It is a cloud-based software compatible with all leading OCT systems, starting with the Heidelberg Engineering Spectralis.
“Over the follow-up of your patients, you can at any time see a curve that shows exactly the biological activity and treatment response, and you no longer have to search and compare with previous images. It is very much hands-on and makes our lives as retinal experts or general ophthalmologists much easier,” Schmidt-Erfurth said. “And it brings the patients on board who are fully informed about their measurements and will increase compliance.”
It is also an incentive to the adoption of shared-care practices, resulting in a more efficient workflow and more time spent with the patient.
“The fluid monitor will bring clinical trial quality to routine clinical care, and at last we should be able to bridge the gap between clinical trial results and real-world outcomes,” Schmidt-Erfurth said.
In addition, cloud-based fluid analysis has the potential to introduce important changes in clinical trials, drastically reducing the variability involved with data collection and analysis. Accessibility of real-time disease condition will speed up recruitment and patient screening, allowing immediate exchange of outcome data with optimal protocol adherence during treatment and a completed data closing right at the end of the study.
“Sponsors, reading centers and everybody involved can immediately get the response of every single patient, and at the end of the study, all the data will be timely available, reliable and transparent. It will save a lot of manpower and budget also in clinical studies,” Schmidt-Erfurth said.
The RetInSight fluid monitor has received the CE mark and Medical Devices Regulation label, currently the highest regulatory approval in Europe. It has been launched there, and an early access program is in place for key opinion leaders.
“We are interested in getting the comments of experts who will be using the fluid monitor in their own practice, and there will be an official launch at Euretina,” Schmidt-Erfurth said.
References:
- Chakravarthy U, et al. Eye (Lond). 2021;doi:10.1038/s41433-020-01354-4.
- RetInSight fluid monitor provides next evolutionary step in monitoring of neovascular age-related macular degeneration. https://retinsight.com/2022/05/17/retinsight-fluid-monitor-provides-next-evolutionary-step-in-monitoring-of-neovascular-age-related-macular-degeneration/. Published May 18, 2022.
For more information:
Ursula Schmidt-Erfurth, MD, PhD, can be reached at Medical University Vienna, Department of Ophthalmology, Waehringer Guertel 18-20, A-1090 Vienna, Austria; email: ursula.schmidt-erfurth@meduniwien.ac.at.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts